Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved rozanolixizumab for ocular symptoms, and insights into current clinical practice.

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...